title: Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.
abstract: OBJECTIVE
  Germ cell tumor (GCT) is the most common malignancy in young adult men. Currently, patients are risk-stratified on the basis of clinical presentation and serum tumor markers. The introduction of molecular markers could improve outcome prediction.
  
  
  METHODS
  Expression profiling was performed on 74 nonseminomatous GCTs (NSGCTs) from cisplatin-treated patients (ie, training set) and on 34 similarly treated patients with NSGCTs (ie, validation set). A gene classifier was developed by using prediction analysis for microarrays (PAM) for the binary end point of 5-year overall survival (OS). A predictive score was developed for OS by using the univariate Cox model.
  
  
  RESULTS
  In the training set, PAM identified 140 genes that predicted 5-year OS (cross-validated classification rate, 60%). The PAM model correctly classified 90% of patients in the validation set. Patients predicted to have good outcome had significantly longer survival than those with poor predicted outcome (P < .001). For the OS end point, a 10-gene model had a predictive accuracy (ie, concordance index) of 0.66 in the training set and a concordance index of 0.83 in the validation set. Dichotomization of the samples on the basis of the median score resulted in significant differences in survival (P = .002). For both end points, the gene-based predictor was an independent prognostic factor in a multivariate model that included clinical risk stratification (P < .01 for both).
  
  
  CONCLUSIONS
  We have identified gene expression signatures that accurately predict outcome in patients with GCTs. These predictive genes should be useful for the prediction of patient outcome and could provide novel targets for therapeutic intervention.
authors.affiliation: Cell Biology Program, Sloan-Kettering Institute for Cancer Research, New York, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Korkola
authors.forename: Jane
authors.initials: J
authors.lastname: Houldsworth
authors.forename: Darren R
authors.initials: DR
authors.lastname: Feldman
authors.forename: Adam B
authors.initials: AB
authors.lastname: Olshen
authors.forename: Li-Xuan
authors.initials: LX
authors.lastname: Qin
authors.forename: Sujata
authors.initials: S
authors.lastname: Patil
authors.forename: Victor E
authors.initials: VE
authors.lastname: Reuter
authors.forename: George J
authors.initials: GJ
authors.lastname: Bosl
authors.forename: R S K
authors.initials: RS
authors.lastname: Chaganti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D020869:Gene Expression Profiling; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D002945:Cisplatin